Drug Database
TR

travoprost + timolol (TTFC, Alcon / TTFC, Alcon)

✓ Approved

Novartis AG · ADRB1 · Small Molecule

What is travoprost + timolol?

travoprost + timolol is a small molecule developed by Novartis AG. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesTTFC, Alcon, TTFC, Alcon
CompanyNovartis AG
Drug ClassSmall Molecule
Molecular TargetADRB1, ADRB2, PTGFR
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

travoprost + timolol acts on 3 molecular targets:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
PTGFRprostaglandin F receptor (FP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

travoprost + timolol is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedIndian journal of ophthalmology2026-08-24

Comparison of manual marking and femtosecond laser-assisted capsular marking methods for toric intraocular lens alignment.

Dinc Dincer D

To compare the effectiveness of femtosecond laser-assisted capsular marking and manual slit-lamp marking methods in correcting astigmatism during cataract surgery, for accurate positioning of toric intraocular lenses (IOLs). The medical records of 35 eyes that underwent preoperative manual marking with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Fort Worth, TX) toric trifocal lens (Group 1), and 35 eyes that underwent the same toric trifocal lens implantation using femtosecond laser IntelliAxis software (Group 2), between 2019 and 2024, were retrospectively reviewed. Pre- and postoperative uncorrected and corrected visual acuity, preoperative corneal astigmatism, postoperative residual astigmatism, and slit-lamp and fundus examinations were evaluated. In the manual-marking group, the mean preoperative corneal astigmatism was 2.11 ± 0.66 D, while the postoperative astigmatism was 0.51 ± 0.17 D. In the femtosecond laser marking group, the mean preoperative corneal astigmatism was 2.06 ± 0.61 D, and the postoperative astigmatism was 0.38 ± 0.13 D. Both groups demonstrated a statistically significant reduction in astigmatism values before and after surgery ( P < 0.05). Postoperative residual astigmatism was lower in the femtosecond group, and the difference between the two groups was statistically significant ( P < 0.05). Both femtosecond laser-assisted and manual-marking methods are effective techniques for toric lens alignment. However, the femtosecond laser-assisted method was found to be statistically superior in correcting astigmatism. Additionally, femtosecond laser marking offers several advantages over manual marking. It is less surgeon-dependent, requires less experience, shortens the procedure time, and eliminates ink-related complications during surgery.

PMID 42635456
Read full article →
PubMedJournal of cataract and refractive surgery2026-08-20

From Earlier to Updated Quadrifocal Intraocular Lens Designs: An Objective Optical Metrology Analysis.

Jeong Eun Ah EA, Bang Seung Pil SP, Pantanelli Seth S, Kang Su Jin SJ et al.

To compare the optical performance of the Clareon PanOptix and Clareon PanOptix Pro intraocular lenses (IOLs) using interferometric metrology and identify measurable optical differences. Physiological Optics Laboratory, Daegu, Republic of Korea. Experimental optical-bench investigation. Three +20.0 D samples each of the PanOptix and PanOptix Pro IOLs (Alcon) were analyzed using a Mach-Zehnder interferometer in a model eye incorporating +0.27 µm corneal spherical aberration. Microscopic imaging, wavefront reconstruction with Zernike analysis, diffractive-step profile reconstruction, point-spread function (PSF)-based retinal image simulation, halo analysis, and through-focus modulation transfer function (TF-MTF) analysis were performed. Both IOLs showed broadly similar diffractive architecture and spherical aberration profiles. Peak-to-valley step-profile amplitudes were comparable, although the PanOptix Pro showed localized differences in the reconstructed step-height contour. PSF-based analyses showed broadly similar focal behavior, but the PanOptix Pro demonstrated clearer Sloan F contour preservation and more evident central PSF-core brightness at the far-intermediate position. In through-focus average MTF (aMTF) profiles, the PanOptix Pro showed a modestly higher far-focus peak and a less pronounced post-peak dip, particularly at 4.5- and 3.0-mm pupils. MTF50 analysis showed a similar overall pattern, with greater variability and more apparent inter-model differences at larger pupil sizes. The PanOptix Pro preserves the fundamental design and spherical aberration profile of the original PanOptix, while showing localized diffractive step-height modifications. Together with clearer far-intermediate F-image preservation, sustained central PSF-core brightness, and a shallower post-peak aMTF dip, these findings are consistent with a relative redistribution of optical energy toward the far-intermediate region, supporting greater far-intermediate optical continuity without substantial changes in nominal add power or overall focal structure.

PMID 42621853
Read full article →
PubMedKlinische Monatsblatter fur Augenheilkunde2026-08-14

Straylight-Based Evaluation of Glare in Two Presbyopia-Correcting Intraocular Lenses.

Kremser Frederick F, Łabuz Grzegorz G, Zielińska Agnieszka A, Khoramnia Ramin R et al.

BACKGROUND: Presbyopia-correcting intraocular lenses (IOLs) provide a complete spectrum of vision but frequently induce dysphotopsia due to multiple focal points and diffractive designs. Standard straylight assessments using a C-Quant meter at a 7° visual angle often show no significant differences between evaluated IOLs. Therefore, evaluating glare effects effectively requires device modifications to demonstrate differences across lower visual angles. This study evaluates glare from the diffractive designs of two presbyopia-correcting IOLs. MATERIAL AND METHODS: This in vitro laboratory study assessed two IOL models: the Clareon PanOptix (Alcon) and the Tecnis Odyssey (J&J Vision). Straylight was measured using a modified C-Quant straylight meter, allowing evaluation at the standard 7° angle as well as lower angles of 2.5° and 3.5°. RESULTS: At 7°, the Clareon PanOptix exhibited straylight of 0.29 ± 0.19 deg2/sr, while the Tecnis Odyssey showed an 8-fold higher value of 2.29 ± 0.60 deg2/sr. At 3.5°, the Clareon PanOptix measured 3.01 ± 0.88 deg2/sr, whereas the Tecnis Odyssey demonstrated more than twice the magnitude at 6.85 ± 0.68 deg2/sr. At the smallest angle of 2.5°, the Clareon PanOptix recorded 4.57 ± 0.12 deg2/sr. In contrast, the Tecnis Odyssey reached 9.34 ± 0.41 deg2/sr, approaching the reference value of a 65-year-old natural crystalline lens. CONCLUSION: The Clareon PanOptix demonstrated substantially lower straylight values across all measured angles compared with the Tecnis Odyssey. This suggests a reduced potential for glare phenomena. Further research using validated patient-reported questionnaires is needed to correlate these objective findings with subjective visual disturbances. QUINTESSENCE: in vitro straylight testing shows that the Clareon PanOptix IOL exhibits lower straylight levels than the Tecnis Odyssey across all measured angles. While clinical confirmation is needed, these findings suggest that the Clareon PanOptix may be associated with a lower risk of dysphotopsia related to its diffractive design.

PMID 42600651
Read full article →
PubMedJournal of clinical medicine2026-08-13

Impact and Limitations of Front-Surface Reflection-Based and Anterior Segment OCT-Derived Keratometry on Refractive Prediction Accuracy in Intraocular Lens Power Calculation.

Miyamoto Sumitaka S, Kamiya Kazutaka K

Objectives: To assess how differences in keratometric measurement principles affect intraocular lens (IOL) power calculation, we compared front-surface reflection-based (FSR) and anterior segment optical coherence tomography (AS-OCT)-derived keratometry (K) values. Methods: This retrospective study included 160 eyes of 160 Japanese patients who underwent cataract surgery with implantation of a CNA0T0 (Alcon) IOL between March 2023 and October 2025. FSR-based keratometry (OA-K, 2.5 mm averaged output ring) was obtained using the OA-2000 (Tomey), whereas AS-OCT-derived keratometry (CA-K, 2.5 mm single ring) and Fourier keratometry (CA-FK, 3.0 mm Fourier analysis zone) were obtained using CASIA2 (Tomey). Predicted refractions were calculated using Barrett Universal II (B-UII) and SRK/T formulas with each K value. Results: Mean K values were 44.14 ± 1.51 D (OA-K), 44.28 ± 1.51 D (CA-K), and 44.40 ± 1.55 D (CA-FK). With the B-UII, the mean absolute error (MAE) was lowest with OA-K (0.27 ± 0.24 D), followed by CA-K (0.28 ± 0.22 D) and CA-FK (0.31 ± 0.23 D). Corresponding MAEs with SRK/T were 0.30 ± 0.26 D, 0.31 ± 0.24 D, and 0.33 ± 0.28 D, respectively. Exploratory subgroup analyses suggested a tendency toward lower prediction accuracy in steep corneas. Differences among keratometric methods were smaller with SRK/T than with B-UII. Conclusions: AS-OCT-derived keratometry did not demonstrate superiority over conventional FSR-based keratometry for IOL power calculation. Further studies are warranted to determine whether AS-OCT-derived keratometry may provide clinical advantages under specific conditions.

PMID 42590071
Read full article →
PubMedJournal of current glaucoma practice2026-08-12

Retinal Pigment Epithelial Detachment Following Topical Travoprost Therapy.

Narapareddy Meghana M, Balakrishnan Narayanan N, Iqbal Mohamed Anjum MA

Prostaglandin analogs, including travoprost, are widely used to lower intraocular pressure in primary open-angle glaucoma. While generally safe, rare posterior segment changes have been reported. Retinal pigment epithelial detachment (RPED) associated with travoprost is uncommon and poorly documented. We report three patients who developed serous RPED shortly after initiating topical travoprost, none of whom had preexisting macular disease. Optical coherence tomography (OCT) confirmed the detachments, and complete anatomical and visual recovery occurred following discontinuation of travoprost and initiation of alternative glaucoma therapy. A clear temporal relationship was observed between drug initiation and RPED onset. The absence of clinical or OCT features suggestive of alternative diagnoses-such as central serous chorioretinopathy, age-related macular degeneration, or pachychoroid spectrum disorders-combined with consistent reversibility, suggests a possible association between travoprost and RPED. These findings emphasize the importance of early recognition and timely intervention, as RPED appears fully reversible when identified promptly, preventing potential persistent visual impairment.

PMID 42582531
Read full article →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-08-11

Can pilocarpine effectively and safely manage glaucoma in the modern era? A systematic review and meta-analysis.

Chen Kai-Yang KY, Chan Hoi-Chun HC, Chan Chi-Ming CM

This study systematically evaluates the efficacy, safety, tolerability, and contemporary clinical positioning of topical pilocarpine in the management of glaucoma and ocular hypertension. This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, EMBASE, Cochrane CENTRAL via the Cochrane Library, Scopus, Web of Science Core Collection, and Google Scholar were searched from inception to 1 May 2026 without language restrictions. Randomized controlled trials and controlled observational studies in adults with glaucoma or ocular hypertension were eligible when topical pilocarpine, used alone or in combination, was compared with placebo, no treatment, laser trabeculoplasty, or other intraocular pressure (IOP)-lowering therapies. The primary outcome was mean change in IOP, and secondary outcomes included responder outcomes, ocular adverse events, discontinuation, visual field outcomes, medication burden, post-laser pressure spikes, and postoperative outcomes. Risk of bias was assessed with the Cochrane Risk of Bias 2.0 tool (RoB 2.0) for randomized studies and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool for nonrandomized studies. We performed random-effects meta-analysis using raw mean difference in mmHg for continuous outcomes and risk ratio (RR) for binary safety outcomes, each reported with a 95% confidence interval (CI); certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Of the 38 studies that met the inclusion criteria, 34 contributed data to the quantitative meta-analysis. In the primary analysis, pilocarpine-containing regimens reduced IOP by an additional 1.16 mmHg compared to all comparators (95% CI 0.84 to 1.47; P < 0.001; I2 = 50.7%). Subgroup analyses suggested larger pooled effects in placebo/no-treatment comparisons, ocular hypertension, primary open-angle glaucoma, and monotherapy studies; however, comparisons with beta-blockers and prostaglandin analogs require cautious interpretation because several large individual trials favored timolol or latanoprost for daily clinical use, tolerability, or dosing convenience. Pilocarpine was associated with a sevenfold higher risk of blurred vision (RR 7.33; 95% CI 3.30 to 16.29) and a sixfold higher risk of discontinuation due to adverse events (RR 6.07; 95% CI 3.69 to 10.00). Egger's test pointed to funnel plot asymmetry (P = 0.003), although the trim and fill method did not impute any missing studies. Pilocarpine lowers IOP effectively, but its modern role is limited by frequent dosing, miosis, blurred vision, accommodative symptoms, brow ache, and higher discontinuation. In current glaucoma care, prostaglandin analogs and selective laser trabeculoplasty are generally more consistent with first-line open-angle glaucoma management, whereas pilocarpine is better positioned for selected clinical scenarios, including angle-closure mechanisms, post-laser pressure-spike prophylaxis, selected postoperative angle-surgery settings, intolerance or nonresponse to other drug classes, and resource-limited settings where newer therapies are unavailable or unaffordable.

PMID 42578995
Read full article →

+7327 more articles available with a free account

Sign up free to view all articles →

Ask about travoprost + timolol